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Reply from the authorsTo the Editor: By means of a metaanalysis of random-
ized trials with cyclosporine (CsA) in autoimmune dis- To the Editor: Ponticelli and colleagues comment on
eases (ADs), Vercauteren et al concluded that the drug the fact that we included in our meta-analysis concerning
leads to a substantial risk of nephrotoxicity (Kidney Int CsA-induced nephrotoxicity in autoimmune diseases
54:536–545, 1998). (Kidney Int 54:536–545, 1998), studies in which CsA was
Their metaanalysis included studies in which CsA was used at higher doses than 5 mg/kg/day, and that only a
used at higher doses than the 5 mg/kg/day threshold few patients given low dose CsA had a persistent increase
recommended by the dosage guidelines [1]. In only a of serum creatinine of 10 to 33%. To be more specific,
few patients given low-dose CsA (all of whom had rheu- only 5 of the 18 included studies used doses of CsA of
matoid arthritis) was a persistent increase in serum creat- more than 5 mg/kg/day. The ‘few’ patients they refer to
inine of 10 to 33% observed. However, in rheumatoid actually consist of 40% of the total population of CsA
arthritis this slight increase in serum creatinine may sim- treated patients (337 patients out of 852). These patients
ply reflect an increase in muscle mass following restored had rheumatoid arthritis and were treated with low-dose
physical activity. CsA (that is, ,5 mg/kg/day), and this important sub-
The authors also underline that CsA may induce renal group of patients exhibited a rise in serum creatinine of
morphological changes. As histological changes were al- 10 to 30%. Indeed, patients with psoriasis or Crohn’s
ready present at pre-treatment biopsy in some patients, disease treated with CsA had a less pronounced increase
it is difficult to assess the impact of CsA. On the other in serum creatinine levels.
hand, in AD patients, CsA-induced morphological changes Ponticelli et al suggest that the rise in serum creatinine
are not always followed by a progressive loss of renal in rheumatoid arthritis patients simply reflects an in-
function [2]. Moreover, CsA nephropathy may be re- crease in muscle mass due to restored physical activity.
versed by drug withdrawal or a dose reduction in both Three studies in rheumatoid arthritis patients [refs. 47,
AD [1] and renal transplant patients [3, 4]. 50, 60 in our article) in which low dose CsA was used,
We believe that the administration of CsA to AD pa- included a control group treated with azathioprine or
tients is safe provided that two golden rules are adopted: D-penicillamine (the other 4 studies were placebo-con-
(a) the dose should never exceed 5 mg/kg/day; (b) the trolled). In these three studies, CsA was therapeutically
dose should be reduced if, in two determinations at two- as effective as azathioprine or D-penicillamine, hence
week intervals, serum creatinine increases to 30% above leading to the same degree of restored physical activity.
baseline, and discontinued if creatinine increases $50%. Yet, the CsA treated groups exhibited a rise of serum
Whenever these recommendations are followed, the risk creatinine between 22 and 30%, whereas the azathio-
of irreversible and progressive renal dysfunction in AD prine or D-penicillamine treated control groups had no
patients is at most minimal. rise at all. Suggesting that this ‘slight’ increase in serum
creatinine is due to the restored physical activity is there-Claudio Ponticelli, Aldo F. Finzi,
and Gianfranco Ferraccioli fore rather simplistic. As already mentioned in our arti-
IRCCS, Ospedale Maggiore and University of Milan; cle, this higher increase in serum creatinine in patients
University of Udine, Milan and Udine, Italy
with rheumatoid arthritis is probably due to the potentia-
tion of the nephrotoxic effects of CsA by NSAIDs, which
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